Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.180
-0.060 (-4.84%)
At close: Jun 12, 2025, 4:00 PM
1.150
-0.030 (-2.54%)
Pre-market: Jun 13, 2025, 7:05 AM EDT
BCLI Employees
Brainstorm Cell Therapeutics had 27 employees as of December 31, 2024. The number of employees decreased by 2 or -6.90% compared to the previous year.
Employees
27
Change (1Y)
-2
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$410,593
Market Cap
9.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BCLI News
- 17 days ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 24 days ago - Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - PRNewsWire
- 4 weeks ago - BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - PRNewsWire
- 5 weeks ago - BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PRNewsWire
- 5 weeks ago - BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - PRNewsWire
- 6 weeks ago - BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - PRNewsWire